行情

CBMG

CBMG

西比曼生物科技集团
NASDAQ

实时行情|Nasdaq Last Sale

15.02
+0.72
+5.04%
交易中 11:59 04/02 EDT
开盘
14.13
昨收
14.30
最高
15.02
最低
14.13
成交量
1.04万
成交额
--
52周最高
18.99
52周最低
10.98
市值
2.91亿
市盈率(TTM)
-5.7215
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CBMG价格均价为23.00,最高价位27.00,最低价为19.00。

EPS

CBMG 新闻

更多
  • Benzinga's Top Upgrades, Downgrades For March 5, 2020
  • Benzinga · 03/05 15:05
  • BTIG Research Downgrades Cellular Biomedicine Gr to Neutral
  • Benzinga · 03/05 09:48
  • Cellular Biomedicine Group's (CBMG) CEO Tony Liu on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/02 16:23
  • Cellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational Progress
  • PR Newswire · 02/28 21:05

所属板块

生物技术和医学研究
+2.33%
制药与医学研究
+1.51%

热门股票

代码
价格
涨跌幅

CBMG 简况

Cellular Biomedicine Group Inc. is engaged in the development of cell therapy technologies. The Company develops cell therapies for the treatment of cancer and degenerative diseases. The Company conducts immuno-oncology and stem cell clinical trials in China using products from the goods manufacturing practices (GMP) laboratory. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. The Company is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases.
展开

微牛提供Cellular Biomedicine Group Inc(NASDAQ-CBMG)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CBMG股票新闻,以帮助您做出投资决策。